Document is current
Any future updates will be listed below
-
Authors
Pearson, Rachael A. https://orcid.org/0000-0002-1107-1969
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/T002735/2)
RCUK | Medical Research Council (MR/V038559/1)
RCUK | Medical Research Council (UKRI3826)
- License Information
-
More Information
Article History
Received: 7 January 2026
Revised: 24 June 2026
Accepted: 7 July 2026
First Online: 25 July 2026
Ethics
Competing interests: RAP has an owner interest in Tower Therapeutics CellX, which has the first option to license the technology to manufacture human cone photoreceptors developed by the KCL Ocular Cell and Gene Therapy group.
